In a report released today, Alex Arfaei from BMO Capital assigned a Sell rating to AbbVie (NYSE: ABBV), with a price target of $78. The company’s shares closed yesterday at $96.25.
According to TipRanks.com, Arfaei is a 4-star analyst with an average return of 5.9% and a 70.4% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Bristol Myers.
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $106.17.
See today’s analyst top recommended stocks >>
The company has a one-year high of $125.86 and a one-year low of $69.38. Currently, AbbVie has an average volume of 8.15M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABBV:
